Skip to main content

Anebulo Pharmaceuticals, Inc.

ANEB
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001815974

No open-market purchases or sales by Anebulo Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Anebulo Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Anebulo Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Anebulo Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Cundy Kenneth CChief Scientific Officer–Apr 7, 20250
Aryeh JasonDirector–Apr 7, 20250
Shah Bimal R.Director–Apr 7, 20250
Cunningham, Richard AnthonyChief Executive Officer–Apr 7, 20250
Lawler Joseph F.Director, 10% Owner–Apr 7, 20250
English Aron R.Director, 10% Owner15,467,300IndirectApr 7, 20250
Lin KennethDirector–Apr 7, 20250
Kupchyk AretaDirector–Apr 7, 20250
Calloway NathanielDirector–Apr 7, 20250
22NW Fund, LP10% Owner15,467,300IndirectDec 26, 20240
22NW, LP10% Owner5,366,290IndirectDec 20, 20230
Allen SimonChief Executive Officer–Dec 13, 20220
Parschauer Karah HerdmanDirector–Oct 3, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 26, 2024 (view filing)4:15 PM ETDec 233 daysEnglish Aron R. and 1 otherDirector, 10% OwnerPPurchase+10.1M$0.99+$10.0M+188.2%15.5M after
Dec 21, 2021 (view filing)8:39 PM ETDec 174 daysEnglish Aron R. and 1 otherDirector, 10% Owner, Other: See Explanation of ResponsesPPurchaseCommon Stock, par value $0.001 per share+400$6.59+$2.63K0.0%3.36M after
Dec 16, 2021 (view filing)11:37 AM ETDec 142 daysEnglish Aron R. and 1 otherDirector, 10% Owner, Other: See Explanation of ResponsesPPurchaseCommon Stock, par value $0.001 per share+412$5.90+$2.43K0.0%3.36M after
Dec 3, 2021 (view filing)7:58 PM ETDec 3Same dayEnglish Aron R. and 1 otherDirector, 10% Owner, Other: See Explanation of ResponsesPPurchaseCommon Stock, par value $0.001 per share+4.50K$5.93+$26.7K+0.1%3.36M after
Dec 3, 2021 (view filing)11:16 AM ETDec 21 dayEnglish Aron R. and 1 otherDirector, 10% Owner, Other: See Explanation ResponsePPurchaseCommon Stock, par value $0.001 per share+13.8K$5.30+$73.3K+0.4%3.36M after